Management of Hepatitis C Infection
Summary
- AASLD/IDSA guidelines recommend glecaprevir/pibrentasvir and sofosbuvir/velpatasvir as the preferred options for genotype 2 HCV–infected patients (Management Guidelines)[AASLD-IDSA HCV]
- Sofosbuvir/velpatasvir/voxilaprevir is the only regimen recommended for genotype 2 HCV–infected patients with sofosbuvir and NS5A inhibitor experience
- EASL guidelines recommend DAA-based regimens for patients with genotype 2 HCV infection (Management Guidelines)[EASL HCV]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment